
Japan's Meiji Holdings Co said on Tuesday its drug subsidiary had started a Phase III trial of an mRNA-based vaccine for COVID-19.
Meiji Seika Pharma had started the late-stage trial among 780 subjects in Japan, with the test period running from November to April 2024, Meiji said in a statement.